Published in Pain on November 01, 2003
Towards a theory of chronic pain. Prog Neurobiol (2008) 2.76
Neurovascular relationship at the trigeminal root entry zone in persistent idiopathic facial pain: findings from MRI 3D visualisation. J Neurol Neurosurg Psychiatry (2005) 1.54
A key role of the basal ganglia in pain and analgesia--insights gained through human functional imaging. Mol Pain (2010) 1.26
Pain, affective symptoms, and cognitive deficits in patients with cerebral dopamine dysfunction. Pain (2012) 1.09
The contribution of the putamen to sensory aspects of pain: insights from structural connectivity and brain lesions. Brain (2011) 1.02
Brain dynamics for perception of tactile allodynia (touch-induced pain) in postherpetic neuralgia. Pain (2008) 1.01
Role of nucleus accumbens in neuropathic pain: linked multi-scale evidence in the rat transitioning to neuropathic pain. Pain (2014) 0.98
Can neuroimaging help us to understand and classify somatoform disorders? A systematic and critical review. Psychosom Med (2011) 0.98
Microglia disrupt mesolimbic reward circuitry in chronic pain. J Neurosci (2015) 0.93
Correlation between ventral striatal catecholamine content and nociceptive thresholds in neuropathic mice. J Pain (2014) 0.88
Dopamine precursor depletion influences pain affect rather than pain sensation. PLoS One (2014) 0.84
Modulation of pain, nociception, and analgesia by the brain reward center. Neuroscience (2016) 0.83
Chronic Back Pain Is Associated with Alterations in Dopamine Neurotransmission in the Ventral Striatum. J Neurosci (2015) 0.83
Spinal dopaminergic projections control the transition to pathological pain plasticity via a D1/D5-mediated mechanism. J Neurosci (2015) 0.83
The striatum and pain modulation. Cell Mol Neurobiol (2011) 0.81
Dopamine and pain sensitivity: neither sulpiride nor acute phenylalanine and tyrosine depletion have effects on thermal pain sensations in healthy volunteers. PLoS One (2013) 0.81
Mesolimbic dopamine signaling in acute and chronic pain: implications for motivation, analgesia, and addiction. Pain (2016) 0.80
Burning mouth syndrome: Current concepts. J Indian Prosthodont Soc (2016) 0.77
Traditional Japanese herbal medicines for treatment of odontopathy. Front Pharmacol (2015) 0.77
Differential dopamine function in fibromyalgia. Brain Imaging Behav (2016) 0.76
Programmed symptoms: disparate effects united by purpose. Curr Rheumatol Rev (2015) 0.76
Transforming pain medicine: adapting to science and society. Eur J Pain (2013) 0.76
Effects of the Fourth Ventricle Compression in the Regulation of the Autonomic Nervous System: A Randomized Control Trial. Evid Based Complement Alternat Med (2015) 0.76
Dopamine in plasma - a biomarker for myofascial TMD pain? J Headache Pain (2016) 0.75
Nigrostriatal dopaminergic depletion increases static orofacial allodynia. J Headache Pain (2016) 0.75
Ilex paraguariensis Promotes Orofacial Pain Relief After Formalin Injection: Involvement of Noradrenergic Pathway. Pharmacognosy Res (2016) 0.75
How Accurate Appraisal of Behavioral Costs and Benefits Guides Adaptive Pain Coping. Front Psychiatry (2017) 0.75
Axis I and II psychiatric disorders after traumatic brain injury: a 30-year follow-up study. Am J Psychiatry (2002) 3.49
Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation (2006) 3.12
Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet (2004) 2.91
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A (2010) 2.32
Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol (2008) 2.24
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging (2010) 2.09
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 2.04
Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2004) 1.93
Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation (2008) 1.82
18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med (2008) 1.77
Effects of sevoflurane, propofol, and adjunct nitrous oxide on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology (2003) 1.70
Effects of surgical levels of propofol and sevoflurane anesthesia on cerebral blood flow in healthy subjects studied with positron emission tomography. Anesthesiology (2002) 1.62
Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med (2010) 1.61
Binge drinking in midlife and dementia risk. Epidemiology (2005) 1.61
Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci (2005) 1.58
The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging (2008) 1.55
Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. Anesthesiology (2006) 1.52
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging (2009) 1.49
The breakdown of fractal heart rate dynamics predicts prolonged postoperative myocardial ischemia. Anesth Analg (2004) 1.47
Effects of intravenous glucose on dopaminergic function in the human brain in vivo. Synapse (2007) 1.46
Consciousness lost and found: subjective experiences in an unresponsive state. Brain Cogn (2011) 1.46
Brain white matter expansion in human obesity and the recovering effect of dieting. J Clin Endocrinol Metab (2007) 1.46
EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging (2009) 1.45
Feasibility and cardiac safety of inhaled xenon in combination with therapeutic hypothermia following out-of-hospital cardiac arrest. Crit Care Med (2013) 1.45
Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br J Clin Pharmacol (2003) 1.42
Interventions for treating burning mouth syndrome. Cochrane Database Syst Rev (2016) 1.39
Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes (2006) 1.37
Returning from oblivion: imaging the neural core of consciousness. J Neurosci (2012) 1.34
Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol (2008) 1.31
Characteristics of two telephone screens for cognitive impairment. Dement Geriatr Cogn Disord (2002) 1.31
Effects of working-memory training on striatal dopamine release. Science (2011) 1.30
Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain (2003) 1.29
Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry (2004) 1.28
Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol (2007) 1.27
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. Anesthesiology (2005) 1.19
Striatal dopamine D2 receptors in modulation of pain in humans: a review. Eur J Pharmacol (2004) 1.17
Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord (2008) 1.15
Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology (2003) 1.14
Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) (2005) 1.14
Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology (2010) 1.13
High intensity exercise decreases global brain glucose uptake in humans. J Physiol (2005) 1.11
Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain. Eur J Nucl Med Mol Imaging (2014) 1.11
Increased brain fatty acid uptake in metabolic syndrome. Diabetes (2010) 1.10
C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse (2009) 1.10
Personality traits and striatal dopamine synthesis capacity in healthy subjects. Am J Psychiatry (2003) 1.08
Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage (2012) 1.07
Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol Imaging Biol (2006) 1.07
Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer (2002) 1.07
Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord (2006) 1.05
Validation of [(11) C]ORM-13070 as a PET tracer for alpha2c -adrenoceptors in the human brain. Synapse (2015) 1.05
Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci Biobehav Rev (2002) 1.04
Mobile phone affects cerebral blood flow in humans. J Cereb Blood Flow Metab (2006) 1.03
Insular dopamine D2 receptors and novelty seeking personality in Parkinson's disease. Mov Disord (2004) 1.03
Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging (2002) 1.02
Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab (2008) 1.02
Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging (2005) 1.02
Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol (2002) 1.01
Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-(11)C]WAY-100635-considerations on the validity of cerebellum as a reference region. J Cereb Blood Flow Metab (2006) 1.00
C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.00
Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ). Mol Imaging Biol (2004) 1.00
Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med (2013) 1.00